BACKGROUND: To the authors' knowledge, the benefit of primary tumor resection among patients with metastatic inflammatory breast cancer (IBC) is unknown. METHODS: The authors reviewed 172 cases of metastatic IBC. All patients received chemotherapy with or without radiotherapy and/or surgery. Patients were classified as responders or nonresponders to chemotherapy. The 5-year overall survival (OS) and distant progression-free survival (DPFS) and local control at the time of last follow-up were evaluated. RESULTS: A total of 79 patients (46%) underwent surgery. OS and DPFS were better among patients treated with surgery versus no surgery (47% vs 10%, respectively [P<.0001] and 30% vs 3%, respectively [P<.0001]). Surgery plus radiotherapy was associated with better survival compared with treatment with surgery or radiotherapy alone (OS rate: 50% vs 25% vs 14%, respectively; DPFS rate: 32% vs 18% vs 15%, respectively [P<.0001 for both]). Surgery was associated with better survival for both responders (OS rate for surgery vs no surgery: 49% vs 23% [P<.0001] and DPFS rate for surgery vs no surgery: 31% vs 8% [P<.0001]) and nonresponders (OS rate for surgery vs no surgery: 40% vs 6% [P<.0001] and DPFS rate for surgery vs no surgery: 30% vs 0% [P<.0001]). On multivariate analysis, treatment with surgery plus radiotherapy and response to chemotherapy were found to be significant predictors of better OS and DPFS. Local control at the time of last follow-up was 4-fold more likely in patients who underwent surgery with or without radiotherapy compared with patients who received chemotherapy alone (81% vs 18%; P<.0001). Surgery and response to chemotherapy independently predicted local control on multivariate analysis. CONCLUSIONS: The results of the current study demonstrate that for select patients with metastatic IBC, multimodality treatment including primary tumor resection may result in better local control and survival. However, a randomized trial is needed to validate these findings.
BACKGROUND: To the authors' knowledge, the benefit of primary tumor resection among patients with metastatic inflammatory breast cancer (IBC) is unknown. METHODS: The authors reviewed 172 cases of metastatic IBC. All patients received chemotherapy with or without radiotherapy and/or surgery. Patients were classified as responders or nonresponders to chemotherapy. The 5-year overall survival (OS) and distant progression-free survival (DPFS) and local control at the time of last follow-up were evaluated. RESULTS: A total of 79 patients (46%) underwent surgery. OS and DPFS were better among patients treated with surgery versus no surgery (47% vs 10%, respectively [P<.0001] and 30% vs 3%, respectively [P<.0001]). Surgery plus radiotherapy was associated with better survival compared with treatment with surgery or radiotherapy alone (OS rate: 50% vs 25% vs 14%, respectively; DPFS rate: 32% vs 18% vs 15%, respectively [P<.0001 for both]). Surgery was associated with better survival for both responders (OS rate for surgery vs no surgery: 49% vs 23% [P<.0001] and DPFS rate for surgery vs no surgery: 31% vs 8% [P<.0001]) and nonresponders (OS rate for surgery vs no surgery: 40% vs 6% [P<.0001] and DPFS rate for surgery vs no surgery: 30% vs 0% [P<.0001]). On multivariate analysis, treatment with surgery plus radiotherapy and response to chemotherapy were found to be significant predictors of better OS and DPFS. Local control at the time of last follow-up was 4-fold more likely in patients who underwent surgery with or without radiotherapy compared with patients who received chemotherapy alone (81% vs 18%; P<.0001). Surgery and response to chemotherapy independently predicted local control on multivariate analysis. CONCLUSIONS: The results of the current study demonstrate that for select patients with metastatic IBC, multimodality treatment including primary tumor resection may result in better local control and survival. However, a randomized trial is needed to validate these findings.
Keywords:
breast cancer; combined modality therapy; inflammatory breast cancer; local control; metastatic breast cancer; multimodality treatment; survival
Authors: L D Curcio; E Rupp; W L Williams; D Z Chu; K Clarke; T Odom-Maryon; J D Ellenhorn; G Somlo; L D Wagman Journal: Ann Surg Oncol Date: 1999 Apr-May Impact factor: 5.344
Authors: N T Ueno; A U Buzdar; S E Singletary; F C Ames; M D McNeese; F A Holmes; R L Theriault; E A Strom; B J Wasaff; L Asmar; D Frye; G N Hortobagyi Journal: Cancer Chemother Pharmacol Date: 1997 Impact factor: 3.333
Authors: P Therasse; S G Arbuck; E A Eisenhauer; J Wanders; R S Kaplan; L Rubinstein; J Verweij; M Van Glabbeke; A T van Oosterom; M C Christian; S G Gwyther Journal: J Natl Cancer Inst Date: 2000-02-02 Impact factor: 13.506
Authors: Elisabetta Rapiti; Helena M Verkooijen; Georges Vlastos; Gerald Fioretta; Isabelle Neyroud-Caspar; André Pascal Sappino; Pierre O Chappuis; Christine Bouchardy Journal: J Clin Oncol Date: 2006-05-15 Impact factor: 44.544
Authors: Eleanor E R Harris; Delray Schultz; Helaine Bertsch; Kevin Fox; John Glick; Lawrence J Solin Journal: Int J Radiat Oncol Biol Phys Date: 2003-04-01 Impact factor: 7.038
Authors: J C Chen; Yaming Li; James L Fisher; Oindrila Bhattacharyya; Allan Tsung; Jose G Bazan; Samilia Obeng-Gyasi Journal: Ann Surg Oncol Date: 2022-06-08 Impact factor: 4.339
Authors: Taiwo Adesoye; Oluwatowo Babayemi; Lauren M Postlewait; Sarah M DeSnyder; Susie X Sun; Wendy A Woodward; Naoto T Ueno; Kelly K Hunt; Anthony Lucci; Mediget Teshome Journal: Ann Surg Oncol Date: 2021-07-22 Impact factor: 5.344
Authors: Vinita Takiar; Catherine L Akay; Michael C Stauder; Welela Tereffe; Ricardo H Alvarez; Karen E Hoffman; George H Perkins; Eric A Strom; Thomas A Buchholz; Naoto T Ueno; Gildy Babiera; Wendy A Woodward Journal: Springerplus Date: 2014-03-31